,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-03-10 03:50:00,Pipeline updates are highly awaited events for investors in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company.,0.19971133768558502,0.006516424939036369,0.7937722206115723,neutral,0.1931949108839035
1,2014-03-10 03:50:00,These companies spend a significant amount in advancing their pipelines.,0.45531466603279114,0.008988481014966965,0.535696804523468,neutral,0.44632619619369507
2,2014-03-10 03:50:00,"One such biopharma company is Omeros Corporation ( OMER ) whose pipeline includes candidates like Omidria (OMS302), OMS103, OMS824 and OMS721.",0.07928866893053055,0.004491101950407028,0.9162201881408691,neutral,0.07479757070541382
3,2014-03-10 03:50:00,"Recently, Omeros announced additional positive results from its phase IIa study on OMS824, for the treatment of schizophrenic patients.",0.9296741485595703,0.015509048476815224,0.05481676012277603,positive,0.9141650795936584
4,2014-03-10 03:50:00,The candidate is Omeros' lead compound in its phosphodiesterase 10 (PDE10) program.,0.1357182413339615,0.006255950778722763,0.858025848865509,neutral,0.12946228682994843
5,2014-03-10 03:50:00,These patients received OMS824 or placebo for a period of two weeks.,0.06267798691987991,0.061169855296611786,0.8761520981788635,neutral,0.0015081316232681274
6,2014-03-10 03:50:00,Patients with schizophrenia were given a higher dose than in any prior OMS824 study.,0.6023141741752625,0.056893687695264816,0.34079208970069885,positive,0.5454204678535461
7,2014-03-10 03:50:00,This caused 50% more plasma concentrations than the earlier reported highest dose.,0.13935835659503937,0.7855324745178223,0.07510919868946075,negative,-0.6461741328239441
8,2014-03-10 03:50:00,"However, OMS824 was tolerated with mild or moderate adverse events that were consistent with those seen in previous cohorts.",0.34601107239723206,0.30796414613723755,0.3460248112678528,neutral,0.03804692625999451
9,2014-03-10 03:50:00,The adverse events were self-limited and did not result in any discontinuation of the candidate.,0.012991044670343399,0.025377696380019188,0.9616312980651855,neutral,-0.012386651709675789
10,2014-03-10 03:50:00,The positive phase II results demonstrate that OMS824 can be administered in combination with standard antipsychotic medications.,0.5384004712104797,0.010146976448595524,0.4514525830745697,positive,0.5282534956932068
11,2014-03-10 03:50:00,A fast-track application is under review in the U.S. for OMS824 for the treatment of schizophrenia.,0.26540011167526245,0.027528950944542885,0.7070708870887756,neutral,0.23787115514278412
12,2014-03-10 03:50:00,Omeros is also evaluating OMS824 for the treatment of patients with symptomatic Huntington's disease (HD).,0.35719120502471924,0.010860003530979156,0.6319487690925598,neutral,0.3463312089443207
13,2014-03-10 03:50:00,The candidate enjoys orphan drug and fast-track designation in the U.S. for HD.,0.8004865050315857,0.02150038443505764,0.17801308631896973,positive,0.7789860963821411
14,2014-03-10 03:50:00,We are encouraged by the pipeline progress at Omeros.,0.9055236577987671,0.013501529581844807,0.08097482472658157,positive,0.8920221328735352
15,2014-03-10 03:50:00,Omeros' most advanced and proprietary pharmacosurgery candidate is Omidria.,0.32771387696266174,0.007747746538370848,0.6645384430885315,neutral,0.3199661374092102
16,2014-03-10 03:50:00,The company is looking to get Omidria approved in the U.S. and EU for the treatment of patients undergoing intraocular lens replacement surgery.,0.8296232223510742,0.01438475213944912,0.1559920459985733,positive,0.8152384757995605
17,2014-03-10 03:50:00,Omeros expects to market Omidria in the second half of 2014 on approval.,0.3485969603061676,0.007793969474732876,0.6436089873313904,neutral,0.34080299735069275
18,2014-03-10 03:50:00,Omeros carries a Zacks Rank #3 (Hold).,0.03036106377840042,0.014513781294226646,0.9551251530647278,neutral,0.015847282484173775
19,2014-03-10 03:50:00,"Investors looking for better-ranked stocks in the biopharma sector may consider companies like Gilead Sciences Inc. ( GILD ), Shire ( SHPG ) and Alkermes ( ALKS ).",0.5680151581764221,0.021377166733145714,0.4106076657772064,positive,0.546638011932373
20,2014-03-10 03:50:00,Gilead Sciences carries a Zacks Rank #2 (Buy) while Shire and Alkermes carry a Zacks Rank #1 (Strong Buy).,0.10107211768627167,0.008035176433622837,0.8908926844596863,neutral,0.0930369421839714
21,2014-03-10 03:50:00,To read this article on Zacks.com click here.,0.01796119473874569,0.019245078787207603,0.9627937078475952,neutral,-0.001283884048461914
22,2014-03-10 03:50:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
